Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. - Wikidata - wikimedia - TriplyDB

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.

http://www.wikidata.org/entity/Q34574285

about

The endocannabinoid system, cannabinoids, and pain Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L Beyond THC: The New Generation of Cannabinoid Designer Drugs The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist The orphan receptor GPR55 is a novel cannabinoid receptor Modulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage.Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis What we know and do not know about the cannabinoid receptor 2 (CB2)Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence Drug models of schizophrenia The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂ Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation Cannabidiol Affects MK-801-Induced Changes in the PPI Learned Response of Capuchin Monkeys (Sapajus spp.).Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice.Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis.Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation.Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats.Cannabinoid Regulation of Brain Reward Processing with an Emphasis on the Role of CB1 Receptors: A Step Back into the Future Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm.A cannabinoid receptor, sensitive to O-1918, is involved in the delayed hypotension induced by anandamide in anaesthetized rats Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III.Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats.Medical use of cannabis. Cannabidiol: a new light for schizophrenia?Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists.Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders.

P2860

Q24601890-6D5FF380-60D2-40BF-B208-8BA5387E4254 Q24605572-82C09619-08D8-45FA-A3DC-90EDDB79DEEE Q24606148-FF41EFC5-FB15-4058-9059-0A0453780851 Q24607361-B77780FB-76A8-45AC-A71E-929EE6906A0B Q24623179-CABC0505-3FB2-4CAC-9D48-D6D5C2E99DFF Q24626361-3C5624E0-1204-4A4E-AFFA-73EF804DD495 Q24635230-933B669C-0C41-41B9-A2E8-BE2C0AA7D492 Q24643876-2F2F57C3-9CBC-4C3E-AAD2-D1E6DE441D54 Q24645241-D93EA31A-A3E1-4FE8-A5B4-DB30E7A88349 Q24646822-710688CE-CE20-40E5-A154-FD471D5828B8 Q24670137-4C7A42C8-A752-432D-A826-E1D7E838BC8D Q27014154-1E46BCB0-A9A1-494F-BA99-88ED61F0AC9E Q27336497-F79161D4-8902-4675-959E-C694B1378D0E Q27497540-FC0805CF-5BBE-453F-A4A7-27CFEFA8E875 Q27686851-8653F2D8-517B-4646-BDDD-44F28E83FCE8 Q28075499-688DF1E7-0ED9-4DE7-8AAD-5DC4408AC34F Q28084198-96A05445-4C78-4FCE-B698-6E6545D993A6 Q28236199-D00843F0-D98F-4049-AFC9-3F836A249408 Q28298445-3FE78904-BA48-477A-9B07-5D90E166A459 Q28554883-4E03E3D3-1544-486F-BBB0-2CF1A9A458D7 Q28576747-9E7AEAC0-8DCD-4620-AC37-EAC355853D60 Q30357558-113F3F39-4229-4671-919D-FFBA1A22CE1B Q30361241-5E716A3B-5064-4F0E-86DD-0997EAD9416E Q30468504-359886DB-8311-4EC0-AD52-4179676D60E7 Q30473707-30042AB5-A3E0-4A1F-873A-5E9CD2161E1A Q30493082-A5638909-9335-4AFF-A849-5C0109ED3376 Q30670447-6A2B2B1A-695A-4132-A479-7B3ED9898925 Q33690796-8E5FD846-AF87-4BC7-8F0E-596EF804DD2E Q33819645-5F9E118C-41CA-4CB0-A4E5-F294281AA9C8 Q33980198-DA33ADFB-908F-4DC1-8E8E-8A5C45AEA4E0 Q34028554-FEAB80BA-A93D-45AF-B490-AEF91E1F3497 Q34095081-A375FF15-BDFF-475C-9891-0D4F246375DC Q34113027-B0FF6717-4200-4D3E-800F-B5636809BC43 Q34137084-18FB491D-6618-41EE-B330-7B365CF48C22 Q34173104-D1FACD6C-8E8F-490F-83A4-95839191A785 Q34192001-CCCAFB4C-6B09-4D26-BB3A-45B636CC34A6 Q34308885-E0BF9E93-41EA-490E-9432-7986C30CC5FD Q34453695-176FF07E-9B31-48DC-8622-655C2888DA9B Q34545629-DCFBE003-6F50-47A0-B52A-FA3EC0EA2051 Q34557613-1A95CA22-E784-4C88-BF76-3B8D38F5E377

P2860

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.

http://www.wikidata.org/entity/Q34574285

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Cannabidiol displays unexpecte ...... B2 receptor agonists in vitro.

@ast

Cannabidiol displays unexpecte ...... B2 receptor agonists in vitro.

@en

Cannabidiol displays unexpecte ...... B2 receptor agonists in vitro.

@nl

type

label

Cannabidiol displays unexpecte ...... B2 receptor agonists in vitro.

@ast

Cannabidiol displays unexpecte ...... B2 receptor agonists in vitro.

@en

Cannabidiol displays unexpecte ...... B2 receptor agonists in vitro.

@nl

prefLabel

Cannabidiol displays unexpecte ...... B2 receptor agonists in vitro.

@ast

Cannabidiol displays unexpecte ...... B2 receptor agonists in vitro.

@en

Cannabidiol displays unexpecte ...... B2 receptor agonists in vitro.

@nl

P1433

Q34574285-073E9F65-8993-4976-993A-ED43D5B1B504

P1476

Q34574285-00E1AB73-5C23-4CDA-8B80-16CC1C561166

P2093

Q34574285-0BFCCA0B-97F0-47D6-B20D-3AD880A37F72

Q34574285-1E684BFC-023D-43C7-A073-F3B4A99F33BE

Q34574285-3DDCFD9F-5E4B-4F80-BD61-73086DDB2159

Q34574285-7839C847-E636-46CB-BDA9-B787ACED291B

Q34574285-C092B2F9-98A0-44AF-BD58-F9E847F41CAE

P2860

Q34574285-2669EE4D-2435-4F72-851D-51CEDCD53EEF

Q34574285-2EF84542-B2D0-4A12-A466-B82DB005AB45

Q34574285-33160E91-A8AD-4C44-8373-D27A88BB0613

Q34574285-37E5AC5F-9AA5-46DF-9BAD-9A49B2C4DC81

Q34574285-60859D32-576E-4F05-8CAC-8D64EE78727F

Q34574285-71D1F055-057F-4339-AA76-51D59B0F9C8E

Q34574285-7792283F-AA93-4584-86AE-B44D4F9F465A

Q34574285-77924F79-7A44-437E-BBA0-EB666B1D9233

Q34574285-7F1A117B-86AD-46F6-8D23-563C3004376D

Q34574285-83B0BDC9-19FD-4265-BD77-4C0C18D150F6

P304

Q34574285-DE8FEA31-E979-4857-A2A7-7D9E4EA06D07

P31

Q34574285-9E8D8FF9-851A-44B6-AA00-4A204CFD40F8

P356

Q34574285-03546B2D-2231-49A5-995B-A13DB6AF7923

P407

Q34574285-14CF5629-0A2C-4716-9028-90E8781CEAA3

P433

Q34574285-AA32F313-02B4-4642-89B5-23F73816D3EB

P478

Q34574285-46C68232-1578-4941-8C78-63B60A29E0BA

P50

Q34574285-FD1F71C0-0B8C-4153-ACA8-5119E2936C1F

P577

Q34574285-29BCBB60-FD7E-499E-977C-6D4D6465A3AD

P5875

Q34574285-5D1D95A5-6B59-4F3D-ABEA-C02A20CB7483

P698

Q34574285-182B2CA3-EC91-4814-AE83-9F22D965AA4A

P921

Q34574285-9a945eff-49b0-0c70-df8b-4af7b7496e2e

P932

Q34574285-6BFCA0AE-E8E4-42CF-B207-04BCD09C96AD

P356

P1433

British Journal of Pharmacology

P1476

Cannabidiol displays unexpecte ...... B2 receptor agonists in vitro.

@en

P2093

A M Phillips

http://www.w3.org/2001/XMLSchema#string

G L Baillie

http://www.w3.org/2001/XMLSchema#string

R A Ross

http://www.w3.org/2001/XMLSchema#string

R G Pertwee

http://www.w3.org/2001/XMLSchema#string

R K Razdan

http://www.w3.org/2001/XMLSchema#string

P2860

75 years of opioid research: the exciting but vain quest for the Holy Grail

Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630

Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors

The two-state model of receptor activation

Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

Pharmacology of cannabinoid receptor ligands.

Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.

P304

613-623

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJP.0707133

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

150

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6558573

http://www.w3.org/2001/XMLSchema#string

P698

17245363

http://www.w3.org/2001/XMLSchema#string

P921

P932

2189767

http://www.w3.org/2001/XMLSchema#string